stockrowSilo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +73.3%
- Free cash flow
- +39.2%
Quarter to June 2026, against a year earlier
Follow SILO
Alert me
Silo Pharma, Inc. (SILO) EV/Sales
As of 6 November 2026, Silo Pharma, Inc. (SILO) trades at a EV/Sales of −52.3×. Over the past ten years it has ranged from −118× (September 2022) to 52,872× (December 2020); the current reading is higher than 14% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −55.6× | — |
| FY2024 | −52.8× | — |
| FY2023 | −41.4× | — |
| FY2022 | −60.4× | — |
| FY2021 | 46.0× | — |
| FY2019 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | −15.2× | — |
| Dec 2025 | −55.6× | — |
| Sep 2025 | 8.0× | — |
| Jun 2025 | −31.9× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. | −52.3× |
| BRTX Biorestorative Therapies, Inc. compare | −5.8× |
| APVO Aptevo Therapeutics Inc. compare | −0.4× |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| EDVA Splash Beverage Group, Inc. compare | 0.8× |
| HCWB HCW Biologics Inc. compare | 1.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)